Denosumab biosimilar (Synermore Biologics)

N/A

Report date: 2024/09/19 14:10:02

Base Information

Drug NameDenosumab biosimilar (Synermore Biologics)
Drug Alias NameSYN109SYN-109
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar
Mechanisms of ActionTumor necrosis factor ligand superfamily member 11 inhibitors
TargetsTumor necrosis factor ligand superfamily member 11
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesSynermore Biologics (Suzhou) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSynermore Biologics (Suzhou) Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A